Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patent DocsGenentech Announces Victory in Cabilly Re-examination
By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry
ADVERTISEMENTS
By Kevin E. Noonan -- Genentech announced last week that the U.S. Patent and Trademark Office had determined it would issue a re-examination certificate in Re-examination Control No. 90/007,542 involving U.S. Patent No. 6,331,415 ("the Cabilly II patent"). While a major victory for Genentech, it represents a bitter defeat for Medimmune, Genentech's licensee, as well as other biotechnology companies affected by Genentech's exclusive rights to basic recombinant DNA technology.The Cabilly II patent claims fundamental methods for making recombinant cells expressing both an immunoglobulin light chain and heavy chain; these methods are useful for making any of several genetically-engineered antibody molecules....Full post as published by Patent Docs on March 02, 2009 (boomark / email).
Lawsuits and Settlements
Exotic Meats USA
Announces Urgent Statewide Recall of Elk Tenderloin
Energy Price Gouging
Inergy Propane announces refunds to customers as part of lawsuit settlement.
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

Genentech, MedImmune settle over Cabilly patent
Cabilly patent faring poorly in re-examination
Patent Office Gives Thumbs Up to Genentechs Cabilly Patent
Roche and Genentech’s Tangled Web
Roche's "Hostile" Bid for Genentech
No Punitive Damages in Genentech Case








